Select region:

Clinical trials located in

Szczecin

Szczecin city is located in Poland. Currently, 20 clinical trials are being conducted in this city.

Szczecin, a city in Poland, boasts a rich history and unique attractions. Founded by the Slavs, it flourished under the Duchy of Pomerania. The city’s landscape is marked by the Oder River, leading to its development as a major seaport. Szczecin’s architectural heritage includes the Pomeranian Dukes’ Castle and the Gothic St. James Cathedral. The city also features the “Floating Garden” – a green space concept that enhances its urban charm. Szczecin played a pivotal role in the Solidarity movement, contributing to Poland’s path to democracy.

  • CT-EU-00042123

    Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    AustriaBelgiumFinlandFranceGermanyHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Evaluating datopotamab deruxtecan & pembrolizumab for advanced lung cancer

    This study compares two treatments for people with a type of lung cancer called ‘non-small cell lung cancer’ that has spread to other parts of the body. It tests whether combining a drug called datopotamab deruxtecan (Dato-DXd) with pembrolizumab works better than using pembrolizumab alone. Aimed at patients with non-small cell lung cancer (NSCLC) who haven’t had previous systemic therapy, it’s especially for those with high PD-L1 tumor expression.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Macitentan and selexipag in ongoing pulmonary hypertension care

    This study is for people with a lung disease called pulmonary hypertension (PH) who have taken part in a previous study and are receiving specific treatment. The main goal of the study is to enable these people to continue treatment even after the previous study has ended. The study involves monotherapy with Macitentan or Selexipag and a combination of Macitentan and Tadalafil at fixed doses. All of these drugs are administered orally. The aim of the study is to check how safe the treatment is when used long-term. Will be monitored if any adverse events occur. If this leads to discontinuation of treatment, this will be reported.

    BelgiumBulgariaPoland
  • Evaluating the efficacy of macitentan in the treatment of high pulmonary artery blood pressure

    This study is checking if a 75 mg dose of a medicine called Macitentan can do a better job for patients with a lung condition called Pulmonary Arterial Hypertension (PAH) compared to a 10 mg dose. The main goal is to see if the 75 mg dose can better delay the patient’s first major health event related to PAH. Major events include things like unplanned hospital stays related to PAH, or their PAH getting worse. The researchers will check if patients’ PAH gets worse by looking at things like their physical exercise ability and signs of heart failure. The study also looks at how patients’ symptoms change from day to day.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSlovakiaSpainSwedenUnited Kingdom
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    AustriaBelgiumFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Comparison of drug combinations in the treatment of advanced lung cancer

    This trial studies a first-line treatment involving Dato-DXd plus pembrolizumab compared to pembrolizumab alone in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The goal is to evaluate the effectiveness and safety of this combined strategy. Target volunteers must not have received any treatments for their advanced or metastatic NSCLC. Participation includes receiving either the combined treatment or pembrolizumab alone. Regular health checks will monitor if any changes or adverse events occur during the trial.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • CT-EU-00041922

    Testing new medication for adult muscle inflammation treatment

    This study aims to test a medicine called Efgartigimod (EFG PH20 SC) for adults who are suffering from a disease called Idiopathic Inflammatory Myopathy (IIM), where muscles become inflamed for unknown reasons. This condition often falls into groups like dermatomyositis, immune-mediated necrotizing myopathy, or specific types of polymyositis. The trial wants to compare how good the medicine is against a placebo. The researchers will look at how much people’s symptoms improve and whether there are any side effects. The test is going to be carried out in many locations and will involve people over 18 years old.

    AustriaBelgiumBulgariaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Study on ruxolitinib cream for hand eczema

    This study investigates the use of ruxolitinib cream for adults with chronic hand eczema, a skin condition causing itchy, red, and cracked skin on the hands. The cream is applied directly to the affected areas twice daily for 16 weeks. Participants in the study, who are adults with moderate to severe hand eczema, are either given ruxolitinib cream or a placebo cream. After 16 weeks, all participants can choose to continue with ruxolitinib cream for another 16 weeks. The study aims to find out if this cream can effectively reduce the symptoms of hand eczema, like itchiness and skin pain, and improve overall skin condition and quality of life. Around 180 people are taking part in this study, which doesn’t include healthy volunteers​.

    GermanyPoland
  • Examining new drug combo vs. standard treatment with pembrolizumab for advanced lung cancer

    This trial is examining if a combination of two medications, Dato-DXd and pembrolizumab, could be superior to using pembrolizumab alone in treating a type of lung cancer known as metastatic non-small cell lung cancer (NSCLC). Participants will include those who have advanced or spread NSCLC and haven’t had systemic treatment for it. The team will be comparing whether the combination treatment can help patients live longer or keep the cancer from growing for a longer period. One group of participants will get pembrolizumab on its own, while another will get both Dato-DXd and pembrolizumab. An important part of the study will assess how the treatment affects the patient’s symptoms and quality of life.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Continued cancer treatment study for osimertinib users

    The ROSY-T study is a follow-up study of patients who used a drug called osimertinib. Researchers will evaluate the effectiveness of treatment with this drug and decide whether patients need to continue using it. This study is open-label, which means that every patient will receive the drug. During treatment, doctors will pay close attention to your health to make sure the medicine is safe.

    FrancePolandUnited Kingdom
  • Testing the effect of the new drug on Crohn’s Disease

    This study is exploring a new medication for Crohn’s disease, an ailment of the gut. The medication, known as BI 706321, is given alongside another medication called Ustekinumab that is already used to treat Crohn’s. The trial is conducted to see if this combination helps to manage the disease better. Participants will be split into two groups. One group will be given the new medication and the other will receive a placebo, alongside Ustekinumab. Participating in this study will last for 1 year. During this time, participants will have about 13 visits to the clinic. Some visits will involve a colonoscopy where doctors look at the intestine’s condition. Their findings will help doctors understand if the new treatment is working.

    BelgiumCzechiaDenmarkGermanyHungaryItalyNetherlandsPolandSpain
  • Comparing remibrutinib and teriflunomide for Multiple Sclerosis

    This study is all about comparing two treatments for relapsing multiple sclerosis (RMS)—a medicine called remibrutinib and another one called teriflunomide. Initially, researchers will do what’s known as a ‘double-blind, which means neither the participants nor the researchers know which treatment the participant takes. This part of the study will involve about 800 people and will go for up to 30 months. After this, the participants can continue the study openly taking remibrutinib for up to 5 years. The study will measure things like how often the MS relapses, changes in disability scale, amount of new lesions, changes in blood markers, walking and arm function, mood, pain, and deviations in various health parameters. There will be a lesser version trial simultaneously, with results from both pooled for analysis.

    BelgiumBulgariaDenmarkItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Studying repotrectinib effect on advanced solid tumors

    In this trial, the researchers are working on a new medicine called Repotrectinib, targeting people with specific types of advanced solid tumors. This medicine might be most helpful if cancer has certain genetic changes, specifically those called ALK, ROS1, or NTRK1-3. It is an early stage of testing Repotrectinib in two parts or phases. During Phase 1,the researchers are trying to find out what the right dose is. It is important to look at the highest dose that can be given without causing too many side effects, and also the dose makes a difference in how the cancer behaves. This phase will also look at how the medication is processed by the body and how it behaves in the system. The second phase will check how well the medicine works in different groups of people, with some details about their cancer and the treatments they have had in the past. It is important to check if the medicine can shrink the tumors and stop them from growing. The researchers will also measure how long these effects last, how quickly these effects occur.

    BelgiumDenmarkFranceGermanyHungaryItalyNetherlandsPolandSpainUnited Kingdom
  • Testing oral ozanimod for active Crohn’s Disease treatment

    This trial is for a medicine called Ozanimod, that’s taken by mouth. It’s a Phase 3 trial, meaning it’s been tested in smaller trials before and looks promising. The disease we’re looking at is Crohn’s Disease, which can be quite severe. The goal of this trial is to see if Ozanimod can help get the disease under control, this is called an ‘induction therapy’. To make sure the results are accurate, some people will get the real medication while others will get a ‘placebo’, which looks the same but doesn’t have any medicine in it. Everything is double-checked to make sure it’s fair and unbiased.

    BulgariaCzechiaFranceItalyPolandUnited Kingdom
  • Study on the effectiveness of Ozanimod in treating Ulcerative Colitis

    This study is focused on evaluating the effectiveness and safety of ozanimod, a medication, in children with active ulcerative colitis, a challenging gastrointestinal condition associated with intense pain. The primary objective of the study is to investigate whether ozanimod, administered orally, can provide relief from the symptoms of active ulcerative colitis in children. Additionally, the study aims to assess the safety profile of ozanimod in this pediatric population.

    BelgiumFranceGermanyPolandSpainUnited Kingdom
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalSlovakiaSloveniaSpainSwedenUnited Kingdom
  • Long-term study on the effectiveness of mirikizumab for Crohn’s Disease

    This research study is about a long-term test of a medicine called Mirikizumab for people who have Crohn’s disease. The main aim of this study is to know if the medicine is effective and safe for those people eventually. The effect of the medicine will be checked using different tests and scores like the Simple Endoscopic Score for Crohn’s Disease, the Crohn’s Disease Activity Index, and patient-reported outcomes. Researchers will also be checking changes in certain markers in the blood and stool that can show inflammation.

    BelgiumCzechiaGermanyHungaryItalyPolandRomaniaSlovakiaSpainUnited Kingdom
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Studying rimegepant’s effectiveness on Migraine

    This study is testing a new treatment, rimegepant, for adults with migraines who cannot take traditional migraine medications, such as triptans, possibly due to reasons like having a heart condition. The research aims to evaluate the effectiveness and tolerability of rimegepant over a 12-week period. Participants will be asked to rate their headache pain on a scale ranging from 0 (no pain) to 3 (severe pain) as one of the methods to assess the treatment’s impact.

    AustriaBelgiumDenmarkFinlandFranceGermanyItalyPolandSpainSwedenUnited Kingdom

See more clinical trials in other cities in Poland:

.